Dyslipidemia needs to be well controlled to prevent cardiovascular risks. And that is found to be possible only with combination therapy than with statin monotherapy. Have a look at this article.

Team@CMHF

PURPOSE OF REVIEW- Residual cardiovascular risk remains in individuals treated with statins and combination therapies may reduce this risk further.

RECENT FINDINGS -Most previous trials of combination therapies have shown a favorable effect on lipid profiles without clinical superiority over statin monotherapy. Trial design has been hampered by short duration and comparison with a low dose statin. The Study of Heart and Renal Protection trial has recently reported findings and shows a benefit of ezetimibe/simvastatin over simvastatin alone.

AIM-HIGH- (Atherothrombosis Intervention in Metabolic syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes), a trial of statin/niacin, has been prematurely halted for futility. Finally, combining a statin with both niacin and ezetimibe shows significant enhancement of the therapeutic effect on lipid profiles.

SUMMARY- Current evidence continues to support initiation of a potent statin with titration to achieve targets. Combinations may be useful in individuals unable to reach desired lipid levels on maximal tolerated doses of statins.

Ref: http://www.docguide.com/combination-therapy-dyslipidemia?forced_voting=1&destination=node%2F1368221%3Fhash%3D80445d1a%26eid%3D21468%26alrhash%3D2efbb8-880279c42369cc2f8adcb48a6daaf3d2